FDA approves Revolution Medicines' pancreatic cancer drug daraxonrasib
The U.S. FDA approved Revolution Medicines' targeted drug daraxonrasib for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy. The drug is the first to target a key molecular cause of the disease and Wall Street expects it to be a major seller.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@BarryMcKokinor
Thoughts? Revolution Medicine (RVMD) — Fast tracked today and received FDA approval. “ The FDA approved a therapy from Revolution Medicines that slows a cancer that kills seven of out eight patients within five years. Wall Street expects Rasonque, which was approved for use in patients for whom other treatments failed, to be a big seller. The drug could generate more than $20 billion in annual sales, according to pharmaceutical commercial intelligence firm Evaluate, if the drug proves to work safely in earlier stages of the disease and with different types of cancers.” - WSJ
@spook008
RVMD!! FDA finally approved their expensive ass drug for pancreatic cancer
@business
Revolution Medicines secured US regulatory approval for its pancreatic cancer drug daraxonrasib, the first medicine to target one of the key molecular causes of the disease https://t.co/2oiFspJBdS
@WSJ
The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years. https://t.co/p1MK3EEwOR
@CNN
The US FDA has approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy. https://t.co/TVpmS4V5j3 https://t.co/HW2OX5Nj7G